Golden
VistaGen Therapeutics

VistaGen Therapeutics

A company developing medicines for depression and other central nervous system disorders

VistaGen Therapeutics is a publicly owned, clinical-stage biopharmaceutical company based in San Francisco, California. The company is focused on developing treatments for depression and other central nervous system (CNS) disorders including, major depressive disorder, neuropathic pain, social anxiety disorder, and suicidal ideation.

VistaGen's product pipeline consists of three items, AV-101, PH10, and PH94B. AV-101 is an oral NMDAR GlyB (N-methyl-D-aspartate receptor glycine B) antagonist, which is a type of glutamate receptor modulators having the potential to treat MDD. Phase 2 clinical trials designed to evaluate the efficacy and safety of it's adjunctive use is ongoing. The US FDA has granted Fast Track designation for AV-101 as both a potential adjunctive treatment of MDD and as a non-opiod treatment for neuropathic pain. The company has also received Notices of Allowances from IP Australia and the Japan Patent Office (JPO) .

PH94B is an intranasal treatment for the rapid onset, on demand treatment of social anxiety disorder (SAD) symptoms. The treatment is developed from VistaGen's proprietary compounds called pherines. Another treatment being developed from pherines, is PH10, which activates nasal chemosensory receptors that in turn engage GABA (gamm-aminubutyic acid) and CRH (corticotropin-releasing hormones) neurons in the hypothalamus, amygdala, prefrontal cortex, and hippocampus. As another potential treatment for MDD, VistaGen is preparing to advance PG10's development in Phase 2b clinical trials.

Timeline

People

Name
Role
Related Golden topics

H. Ralph Snodgrass

Founder, President, Director & Chief Scientific Officer

Jerrold D. Dotson

VP & CFO and Secretary

Mark A. McPartland

VP of Corporate Development

Mark A. Smith

Chief Medical Officer

Oscar Baranchuk

Investor

Rajiv Gujral

Investor

Shawn K. Singh

Director & CEO

Susan E Caldwell, PhD

Employee

Further reading

Title
Author
Link
Type

VistaGen Therapeutics Acquires Worldwide Rights to Develop and Commercialize PH10, a First-in-Class Intranasally Administered Neuroactive Steroid with Rapid-onset Antidepressant Effects for Major Depressive Disorder Demonstrated in Phase 2a Study

VistaGen Therapeutics

Web

VistaGen Therapeutics Receives Notices of Allowance in Australia and Japan for AV-101 Patents Covering Treatment of Depression

VistaGen Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References